FINWIRES · TerminalLIVE
FINWIRES

RBC Removes Speculative Risk From Revolution Medicines, Raises Price Target to $251 From $203, Keeps Outperform Rating

By

Revolution Medicines (RVMD) has an average rating of buy and mean price target of $235.82, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Wolfe Research Downgrades Intuit to Peer Perform From Outperform

Intuit (INTU) has an average rating of overweight and mean price target of $425.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $344.52, Change: $-12.95, Percent Change: -3.62%

$INTU
Research

Tigress Financial Initiates Jersey Mike's Subs at Buy With $29 Price Target

Jersey Mike's Subs (JMKE) has an average rating of buy and mean price target of $28.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $22.27, Change: $+0.06, Percent Change: +0.27%

$JMKE
Research

UBS Downgrades SAP to Neutral From Buy

UBS Downgrades SAP to Neutral From Buy

$SAP